Saratoga Technologies Launches FDA-Cleared Laserase Thulium Laser

Got story updates? Submit your updates here. ›

Saratoga Technologies, L.L.C. has unveiled Laserase, an FDA-cleared 1927nm Thulium laser system that combines micro-ablative and non-ablative treatments to address a wide range of skin concerns, including pigmentation disorders, photoaging, fine lines, wrinkles, and more. The platform is safe for all skin types, eliminates recurring consumable costs, and enables deeper absorption of topical treatments.

Why it matters

Laserase represents a significant advancement in laser skin rejuvenation technology, offering a versatile platform that can address multiple skin concerns with superior safety and efficacy. Its ability to stimulate collagen remodeling and enhance topical delivery of treatments makes it an attractive option for both providers and patients seeking comprehensive skin care solutions.

The details

The Laserase platform uses a 1927nm Thulium laser to deliver both micro-ablative and non-ablative treatments. This dual-action approach allows it to address a wide range of skin concerns, including pigmentation disorders, photoaging, fine lines, wrinkles, acne scarring, uneven texture, sun damage, melasma, freckles, post-inflammatory hyperpigmentation (PIH), actinic keratosis, enlarged pores, skin laxity, and hair/scalp conditions. The system is safe for all Fitzpatrick skin types (I-VI) and carries a minimal risk of PIH.

• Laserase was unveiled by Saratoga Technologies, L.L.C. on February 17, 2026.
• The Laserase system is now available for demonstration and purchase in the United States.

What they’re saying

What’s next

Laserase is now available for demonstration and purchase in the United States, with exclusive previews, priority delivery, and IRS Section 179 eligibility.